CTXR - Citius Pharmaceuticals Inc Stock Price, Fair Value and News

$1.15-0.11 (-8.73%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CTXR Price Action

Last 7 days

-17.9%

Last 30 days

-24.3%

Trailing 12 Months

-67.6%

CTXR RSI Chart

CTXR Valuation

Market Cap

19.6M

Price/Earnings (Trailing)

-0.46

Price/Sales (Trailing)

742.41

EV/EBITDA

-0.33

Price/Free Cashflow

-0.95

CTXR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CTXR Fundamentals

CTXR Revenue

Revenue (TTM)

29.3K

CTXR Earnings

Earnings (TTM)

-42.1M

Earnings Growth (Yr)

12.95%

Earnings Growth (Qtr)

20.05%

CTXR Profitability

EBT Margin

-140251.16%

Return on Equity

-64.67%

Return on Assets

-32.95%

Free Cashflow Yield

-105.22%

CTXR Investor Care

Shares Dilution (1Y)

135.33%

Diluted EPS (TTM)

-4.97

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2014	34.6K	29.3K	0	0
2013	22.1K	18.7K	29.1K	0
2012	12.6K	12.9K	15.6K	0
2011	0	0	13.4K	7.6K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

CEO	Mr. Leonard L. Mazur
WEBSITE	citiuspharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	21

Citius Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Citius Pharmaceuticals Inc? What does CTXR stand for in stocks?

CTXR is the stock ticker symbol of Citius Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Citius Pharmaceuticals Inc (CTXR)?

As of Wed Dec 03 2025, market cap of Citius Pharmaceuticals Inc is 19.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTXR stock?

You can check CTXR's fair value in chart for subscribers.

Is Citius Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CTXR is over valued or under valued. Whether Citius Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Citius Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTXR.

What is Citius Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, CTXR's PE ratio (Price to Earnings) is -0.46 and Price to Sales (PS) ratio is 742.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTXR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Citius Pharmaceuticals Inc's stock?

In the past 10 years, Citius Pharmaceuticals Inc has provided -0.463 (multiply by 100 for percentage) rate of return.